Lonza Announces Agreement to Manufacture AstraZeneca’s COVID-19 Long-Acting Antibody Combination
Lonza announced today that the company has signed an agreement with AstraZeneca to manufacture AZD7442, a combination of two long-acting antibodies (LAABs) for the potential prevention and treatment of COVID-19.
October 30, 2020